Study shows first-of-its kind gene therapy can restore vision to people with an inherited retinal disorder
Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.
Patients in the study had a condition called Leber congenital amaurosis (LCA), which begins in infancy and progresses slowly, eventually causing complete blindness. This new, first-of-its kind gene therapy is currently under review by the U.S. Food and Drug Administration for potential approval this year. There are currently no treatments available for inherited retinal diseases.
Ophthalmologist Stephen R. Russell, M.D., of the University of Iowa, is one of the lead researchers for this pioneering treatment. Data from the first randomized, controlled, phase 3 study showed that 27 of 29 treated patients (93 percent) experienced meaningful improvements in their vision, enough that they could navigate a maze in low to moderate light. They also showed improvement in light sensitivity and peripheral vision, which are two visual deficits these patients experience.
Approval could open the door for other gene therapies that could eventually treat the more than 225 genetic mutations known to cause blindness. It could be applied to retinitis pigmentosa, another inherited retinal disease caused by a defective gene. Or in the future, gene therapy could possibly provide key proteins needed to restore vision in more common diseases such as age-related macular degeneration.
LCA is rare, affecting about 1 in 80,000 individuals. It can be caused by one or more of 19 different genes. The treatment, called voretigene neparvovec (Luxturna, Spark Therapeutics), involves a genetically modified version of a harmless virus. The virus is modified to carry a healthy version of the gene into the retina. Doctors inject billions of modified viruses into both of a patient’s eyes.
Treatment doesn’t restore normal vision. It does, however, allow patients to see shapes and light, allowing them to get around without a cane or a guide dog. It is unclear how long the treatment will last, but so far, most patients have maintained their vision for two years.
More than 200 patients with LCA have participated in gene therapy trials since 2007.
However, no gene therapy has gotten this close to FDA approval for retinal disease or any other eye disease. In October, an advisory committee to the FDA unanimously endorsed the treatment. The FDA isn’t obligated to follow the recommendations of its advisory committees, but it usually does. The agency is expected to make its decision no later than January 2018.
The Latest on: Gene therapy
- A New Gene-Editing Therapy Would Benefit Kids Most—Here’s Why They Won’t Get It Yet on November 18, 2017 at 9:57 am
A patient in the U.S. has become the first person to receive an injection of an experimental therapy meant to edit a genetic error in his DNA. The use of gene editing to correct cells in the body represents a scientific milestone, but the case also points ... […]
- ZIOPHARM to update investors on gene therapy candidate for brain cancer November 20 on November 17, 2017 at 8:24 pm
ZiOPHARM (NASDAQ:ZIOP) will host a conference call on Monday, November 20 at 10:15 am ET to discuss updated clinical data on its interleukin-12 (IL-12) gene therapy candidate for brain cancer. The results will be presented at the 22nd Annual Meeting and ... […]
- Adult Stem Cells and Gene Therapy Save a Young Boy With Horrible Skin Condition on November 17, 2017 at 3:34 pm
When people talk about something that “saved their skin,” they usually mean that it helped them out of a difficult situation. But a young boy in Germany has literally had his skin—and his life—saved through the use of genetically-engineered adult ... […]
- How to Avoid a Disastrous Gene-Therapy Price Battle on November 17, 2017 at 11:00 am
Drugs that modify human genes have the potential to cure intractable diseases with just one treatment. Few could disagree that's a good thing. But if these same drugs cost $1 million or more a pop, then the disagreements begin. Philadelphia gene-therapy ... […]
- Texas man with eyesight issues hopes gene therapy can help on November 17, 2017 at 10:50 am
DALLAS (AP) - When he was 9, Mason Two Crow learned he could be legally blind before he turned 18. A few years later, his doctors told him something else: Researchers were working on a treatment that could save his vision. But the therapy would have to ... […]
- Can Spark make a profit on its groundbreaking gene therapy? on November 17, 2017 at 5:15 am
Spark Therapeutics is on the cusp of gaining the first ever approval for a gene therapy from the FDA, a groundbreaking treatment which restores vision to children and adults with a rare inherited blindness. Last month an FDA advisory committee voted ... […]
- F.D.A. Speeds Review of Gene Therapies, Vowing to Target Rogue Clinics on November 16, 2017 at 9:48 pm
The Food and Drug Administration on Thursday issued new guidelines to speed the introduction of treatments involving human cells and tissues, including gene therapy. But the agency also said it would crack down on rogue clinics offering dangerous or ... […]
- Gene Therapy Is Revolutionary Science That Can Cure Blindness. Is It Worth $1 Million a Pop? on November 16, 2017 at 1:17 pm
A new report by the U.S. Institute for Clinical and Economic Review (ICER) suggests that the potential $1 million list price for Spark Therapeutics’ gene therapy Luxturna—which recently received a unanimous FDA advisory committee recommendation to ... […]
- $1 million price tag in spotlight as gene therapy becomes reality on November 16, 2017 at 1:14 pm
LONDON (Reuters) - Battle lines are being drawn as the first gene therapy for an inherited condition nears the U.S. market, offering hope for people with a rare form of blindness and creating a cost dilemma for healthcare providers. Spark Therapeutics ... […]
- US scientists try editing gene inside body for first time, hope to cure disease on November 15, 2017 at 8:45 am
If it's successful, it could give a major boost to the fledgling field of gene therapy. Scientists have edited people's genes before, altering cells in the lab that are then returned to patients. There also are gene therapies that don't involve editing DNA. […]
via Google News and Bing News